HomeAI · summaries
Storia in 2 fonti
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - VolitionRX (AMEX:VNR
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
- ·
benzinga.com
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - VolitionRX (AMEX:VNR
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.